A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight but Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Study identifier:D7830C00001

ClinicalTrials.gov identifier:NCT04142424

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight but Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Medical condition

Metabolic disorders

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2693, Placebo

Sex

All

Actual Enrollment

73

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 28 Oct 2019
Primary Completion Date: 12 Nov 2021
Study Completion Date: 12 Nov 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria